Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

Context A portion of patients with chronic myeloid leukaemia (CML) develop resistance to the Bcr-Abl tyrosine kinase inhibitors (TKIs), limiting the clinical applications. Previous results have demonstrated the synergistic effects between cryptotanshinone (CPT) and imatinib on apoptosis of CML cells...

Full description

Bibliographic Details
Main Authors: Rubin Cheng, Yilan Huang, Yun Fang, Qirui Wang, Meixiu Yan, Yuqing Ge
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Pharmaceutical Biology
Subjects:
imatinib resistance
second-generation tki
cml xenograft models
stat3 signalling pathway
Online Access:http://dx.doi.org/10.1080/13880209.2021.1944224

Internet

http://dx.doi.org/10.1080/13880209.2021.1944224

Similar Items